China's Sinovac reveals capacity ramp-up for its Covid-19 vaccine
With construction of third production line finished, biotech company says it can manufacture two billion doses annually
Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, announced that the third production line of its CoronaVac-branded Covid vaccine was completed and put into commercial production. The company says it has been inspected by China’s National Medical Products Administration (NMPA) in compliance with quality requirements.
According to Sinovac, its annual capacity of CoronaVac has reached 2 billion doses (including this new production line). Over 200 million doses have been delivered to more than 20 countries, including China, with more than 100 million estimated doses of the vaccine having been administered.
At this point, CoronaVac has received emergency use authorization (EUA), or conditional marketing authorization, by over 30 countries. Its facility and quality management system has been inspected by China, Brazil, Indonesia, Chile, Singapore and Saudi Arabia, along with the World Health Organization (WHO).
